Cabaletta Bio Q1: R&D $37.4M, cash $116.6M; $150M equity raise; rese-cel advances

Cabaletta Bio, Inc.

2026-Q1 EPS reported -$0.39

R&D expenses $37.4M (up 29% YoY); G&A $6.9M (down 15% YoY); cash $116.6M as of March 31, 2026.
Post-quarter $150M registered direct offering closed in May 2026, extends cash runway into mid-2027.
Preconditioning-free rese-cel data presented at ASGCT; lowest dose showed drug-free responses in 4 PV patients.
Registrational RESET-Myositis trial progressing with BLA submission planned for 2027; higher dose and longer-term data expected 2H26.
Entered 10-year commercial supply agreement with Cellares for automated manufacturing of rese-cel.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cabaletta Bio, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

308 earnings releases filed in the last 30 days. Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001759138-26-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.